Gestala

What Gestala does

Gestala (Chengdu) Technology Co., Ltd. (格式塔（成都）科技有限公司) is a privately held Chinese life-sciences enterprise founded January 1, 2026, by Phoenix Peng (Peng Lei, former CEO of NeuroXess) and Chen Tianqiao (founder of Shanda Group). It is positioned as China's first company specializing in ultrasound-based non-invasive brain-computer interface (BCI) technology, targeting whole-brain read and write capabilities through focused ultrasound neuromodulation that stimulates neural pathways transcranially without surgical implants. The company is developing a three-stage product roadmap: a first-generation Class III clinical device targeting the anterior cingulate cortex for chronic pain management; a wearable home-use helmet for depression, stroke recovery, and sleep disorders; and an ultimate closed-loop system for automatic real-time brain-state detection and stimulation. Applications also include PTSD and blood-brain barrier opening as documented research areas on its scientific platform.

The underlying technology is a non-invasive ultrasound neuromodulation platform, differentiated from invasive BCI competitors such as Neuralink by eliminating the need for surgical implants. Gestala plans to submit its Class III medical device registration application to China's NMPA by the end of 2026, with first production line completion targeted for Q2 2026 and first-generation device production targeted for Q3 2026. Revenue mechanics are anticipated to combine hardware sales of medical devices to hospitals and healthcare providers (initial focus), expansion into hospital clinical service partnerships, and a longer-term consumer wearable hardware channel for home use. Pricing has not been disclosed.

Operationally, Gestala is headquartered in Chengdu (which also houses its manufacturing facility at Tianfu International Bio-City) with offices in Shanghai and Hong Kong, and is rapidly scaling from an initial 15-person team to approximately 40 employees by year-end 2026, concentrated in R&D across AI and neuroscience. The company is venture-backed, having closed a CNY 150 million (~US$21.6M) angel round in March 2026 — the largest early-stage BCI financing in China — co-led by Guosheng Capital and Daotong Investment, with reported total investor commitments exceeding CNY 390 million. Its Scientific Advisory Board includes globally top-ranked neuroscientist Trevor Robbins, Fudan University ISTBI Dean Jianfeng Feng, and former Neuralink Clinical Partnerships Lead Bashar Badran. Strategic partners include Fourier Intelligence (BCI plus embodied intelligence) and Chengdu municipal industrial programs.

Name

Gestala

Legal name

Gestala (Chengdu) Technology Co., Ltd. (格式塔（成都）科技有限公司)

Website

https://www.gestala.com/

Company type

Private

Founded year

2026

Operating status

Operating

Headcount range

11–50 employees

Short description

Gestala is a Chinese life-sciences startup developing non-invasive ultrasound brain-computer interface technology for whole-brain neuromodulation, targeting chronic pain, depression, stroke recovery, PTSD, and sleep disorders through Class III medical devices and planned consumer wearables for hospitals and home users.

Ownership category

akta.pro rank

Product category

Brain-Computer Interface Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

Keywords

• Brain-computer interface
• Ultrasound neuromodulation
• Non-invasive BCI
• Neural stimulation devices
• Medical brain devices

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Sale of Class III medical devices for neurological disorder treatment. First product targeting chronic pain management, with pipeline for depression, PTSD, stroke rehabilitation, and sleep disorders.
2. Clinical Healthcare Services: Hospital and healthcare provider partnerships for BCI treatment delivery in clinical settings
3. Wearable Consumer Devices: Planned home-use wearable helmet devices for ongoing neurological condition management including depression and sleep disorders

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Gestala develops non-invasive ultrasound-based brain-computer interface (BCI) medical devices that read and stimulate brain activity through the skull without surgical implants. Its first-generation clinical device targets chronic pain by modulating the anterior cingulate cortex, with a follow-on wearable home helmet for depression, stroke recovery, and sleep disorders, and an ultimate closed-loop platform for automatic brain state detection and stimulation.

Product overview

Gestala is developing a multi-stage portfolio of ultrasound-based brain-computer interface products. The company is building a clinical chronic pain management device targeting the anterior cingulate cortex as its first commercial product, followed by a wearable home helmet for depression, stroke recovery, and sleep disorders. The ultimate platform goal is a closed-loop ultrasonic brain-machine interface system capable of detecting and automatically stimulating abnormal brain states in real-time. All products utilize non-invasive ultrasound technology for neural reading and stimulation without surgical implants.

Differentiator

Problem solved

Functional benefit

Products and services

• First-Generation Chronic Pain Management Device A Class III clinical medical device for chronic pain treatment that uses focused ultrasound to stimulate the anterior cingulate cortex without surgery. Designed for hospital and clinical settings, targeting patients requiring non-invasive neurological intervention for chronic pain.
• Wearable Home Helmet Device A planned consumer-grade wearable helmet that uses focused ultrasound to detect and treat brain states associated with depression, stroke recovery, and sleep disorders. Targeted at home users for ongoing neurological condition management.
• Closed-Loop Ultrasonic Brain-Machine Interface System A next-generation closed-loop ultrasonic BCI platform intended to automatically detect abnormal brain states and deliver stimulation in real time, with whole-brain read-write capabilities across neurological and psychiatric conditions.

Quantifiable outcome

• First production line completion targeted for Q2 2026 with first-generation chronic pain product entering production in Q3
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Fourier IntelligencecoreStrategic or Co-development Partner · 12 March 2026Strategic partnership announced January 28, 2026 combining BCI technology with embodied intelligence (robotics). Gestala and Fourier Intelligence collaborating on integration of ultrasound brain-computer interfaces with robotics/embodied AI systems.

Scale indicators4 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Neuralink: Neuralink is the highest-profile brain-computer interface company developing implantable BCIs for neurological conditions. It is Gestala's most-cited direct competitor — both target chronic pain, depression, and motor recovery, but Neuralink uses surgical implants while Gestala uses non-invasive ultrasound.
• BrainCo: BrainCo is a Chinese-founded BCI company developing both consumer wearables (Focus series) and prosthetic/medical applications. It is a direct competitor in the China and global non-invasive BCI consumer market that Gestala's planned home helmet would address.
• Blackrock Neurotech: Blackrock Neurotech develops invasive BCIs for clinical research and patient applications. It competes with Gestala for the same chronic neurological condition treatment market but takes a surgical-implant approach rather than ultrasound.
• Synchron: Synchron develops a stent-based BCI that is less invasive than Neuralink's implants and is in human clinical trials. It is a direct peer in the race for clinically usable BCI, and competes with Gestala for similar patient populations including those with paralysis and motor impairment.
• Precision Neuroscience: Precision Neuroscience develops a minimally invasive cortical interface BCI. It is a direct peer in the next-generation BCI category targeting neurological disease treatment and competes for similar patient populations and clinical trial sites.
• NeuroXess: NeuroXess is a Chinese invasive BCI company developing neural interface implants. It is a direct Chinese competitor to Gestala, and notably Phoenix Peng (Gestala's founder/CEO) is NeuroXess's former CEO, making this an exceptionally close comparable for technology, market, and team dynamics.

Broad incumbents

• Medtronic: Medtronic is the incumbent leader in implantable neuromodulation (DBS, SCS, VNS) for chronic pain, Parkinson's, epilepsy, and depression. Gestala's chronic-pain and depression pipeline directly competes with Medtronic's installed base and reimbursement infrastructure.
• Boston Scientific: Boston Scientific owns the WaveWriter SCS system and Vercise DBS system, making it a broad incumbent neuromodulation competitor to Gestala in chronic pain and movement disorder treatment markets.
• Abbott: Abbott operates the second-largest neuromodulation franchise (Proclaim DBS, Infinity DBS) and competes directly with Gestala in chronic pain and movement disorder treatment with an established hospital sales channel and reimbursement pathways.

Emerging players

• Magstim / Brainsway: Brainsway develops deep transcranial magnetic stimulation (dTMS) systems for depression and OCD, and Magstim is a leading TMS manufacturer. Both compete with Gestala's non-invasive approach to depression and neurological disorder treatment using established, FDA-cleared electromagnetic modalities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gestala

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gestala